CME Just Hiked Silver Margins and Triggered a 46% Crash From All-Time Highs — Is the Worst Over?March 19, 2026
Share Facebook Twitter LinkedIn Pinterest Email Pfizer posts late-stage trial win for Talzenna plus Xtandi in new prostate cancer indication
ACCESS Newswire Non-GAAP EPS of $0.17 beats by $0.01, revenue of $5.79M misses by $0.05MMarch 19, 2026